Atara biotherapeutics to participate in cell therapy panel discussion at the citigroup 17th annual biopharma conference

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that pascal touchon, president and chief executive officer, will participate in a cell therapy panel discussion at the citigroup 17th annual biopharma conference on wednesday, september 7, 2022 at 6:4
ATRA Ratings Summary
ATRA Quant Ranking